Advertisement
U.S. markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.52+0.06 (+0.80%)
At close: 04:00PM EST
7.52 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close7.46
Open7.32
Bid3.25 x 4000
Ask7.72 x 800
Day's Range7.20 - 7.66
52 Week Range6.20 - 18.65
Volume86,294
Avg. Volume77,123
Market Cap130.296M
Beta (5Y Monthly)0.14
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nuvectis Pharma, Inc.
    Daily – Vickers Top Insider Picks for 10/31/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Simply Wall St.

    Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership

    Key Insights Nuvectis Pharma's significant insider ownership suggests inherent interests in company's expansion The top...

  • GlobeNewswire

    Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

    Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event Oppenheimer 34th Annual Healthcare Life Sciences Conference Dat

  • GlobeNewswire

    Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

    Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event Oppenheimer 34th Annual Healthcare Life Sciences Conference Dat